ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 117 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,155,622 | -33.9% | 898,631 | 0.0% | 0.67% | +4.8% |
| Q2 2023 | $9,318,803 | +28.2% | 898,631 | 0.0% | 0.64% | +27.6% |
| Q1 2023 | $7,269,925 | +51266.7% | 898,631 | 0.0% | 0.50% | -69.1% |
| Q4 2022 | $14,153 | -99.9% | 898,631 | 0.0% | 1.63% | +4.4% |
| Q3 2022 | $14,144,000 | +12.7% | 898,631 | 0.0% | 1.56% | +23.9% |
| Q2 2022 | $12,545,000 | -19.0% | 898,631 | 0.0% | 1.26% | +18.1% |
| Q1 2022 | $15,492,000 | +15.7% | 898,631 | -2.4% | 1.07% | +32.2% |
| Q4 2021 | $13,391,000 | -20.9% | 920,982 | -2.1% | 0.81% | +6.2% |
| Q3 2021 | $16,934,000 | -29.8% | 940,754 | -31.5% | 0.76% | -27.3% |
| Q2 2021 | $24,132,000 | -41.9% | 1,374,279 | -16.6% | 1.04% | -28.4% |
| Q1 2021 | $41,510,000 | +289.5% | 1,647,214 | 0.0% | 1.46% | +206.5% |
| Q4 2020 | $10,657,000 | +151.8% | 1,647,214 | 0.0% | 0.48% | +94.3% |
| Q3 2020 | $4,233,000 | +58.7% | 1,647,214 | 0.0% | 0.24% | +28.3% |
| Q2 2020 | $2,668,000 | +55.8% | 1,647,214 | 0.0% | 0.19% | +23.2% |
| Q1 2020 | $1,713,000 | -52.5% | 1,647,214 | 0.0% | 0.16% | -54.1% |
| Q2 2019 | $3,607,000 | -63.4% | 1,647,214 | 0.0% | 0.34% | -65.7% |
| Q1 2019 | $9,867,000 | -18.9% | 1,647,214 | 0.0% | 0.98% | -36.7% |
| Q4 2018 | $12,173,000 | -49.1% | 1,647,214 | 0.0% | 1.56% | -35.5% |
| Q3 2018 | $23,918,000 | -27.3% | 1,647,214 | 0.0% | 2.41% | -43.1% |
| Q2 2018 | $32,895,000 | +14.0% | 1,647,214 | 0.0% | 4.24% | +3.7% |
| Q1 2018 | $28,859,000 | -29.0% | 1,647,214 | 0.0% | 4.09% | -53.0% |
| Q4 2017 | $40,620,000 | -44.9% | 1,647,214 | -42.4% | 8.70% | -41.6% |
| Q3 2017 | $73,780,000 | -4.8% | 2,858,569 | 0.0% | 14.91% | -23.6% |
| Q2 2017 | $77,524,000 | -9.1% | 2,858,569 | 0.0% | 19.52% | -22.1% |
| Q1 2017 | $85,243,000 | -4.3% | 2,858,569 | -12.9% | 25.08% | -14.6% |
| Q4 2016 | $89,116,000 | -17.0% | 3,283,569 | -21.7% | 29.37% | -12.2% |
| Q3 2016 | $107,342,000 | +38.7% | 4,191,397 | 0.0% | 33.45% | +58.2% |
| Q2 2016 | $77,415,000 | -2.5% | 4,191,397 | 0.0% | 21.14% | +6.1% |
| Q1 2016 | $79,427,000 | – | 4,191,397 | – | 19.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |